How China's innovative pharmaceutical industry accelerates with regulatory reform

Basic Applied Science
14 followers
1 Video View·Aug 9, 2026
Regulatory reforms have accelerated innovation in China's pharmaceutical industry by shortening approval times, encouraging new drug research, raising international standards, and promoting clinical trials. Consequently, domestic enterprises have enhanced their innovation capabilities and global competitiveness.
A newly approved treatment for narcolepsy is marking a milestone in China's pharmaceutical
industry. For people living with narcolepsy, staying awake can be a daily challenge.
The rare neurological disorder causes overwhelming daytime sleepiness,
with patients sometimes falling asleep while talking, eating, and even working.
China has now approved a first in-class medicine for type 1 narcolepsy in patients aged 16 and
above. Developed through a global multicenter clinical program, the drug received its first
regulatory approval in China after being submitted simultaneously in multiple markets.
Officials say faster review procedures for innovative medicines with significant
clinical advantages are helping bring more global developed drugs to China at an early stage.
We have accelerated the review and approval of innovative medicines that address life-threatening
diseases and offer significant clinical advantages. That is helping bring more
globally developed innovative drugs to China at an earlier stage.
The trend is also reflected in clinical research. Official data shows China registered 410
international multicenter clinical trials in 2025, more than double the number in 2020.
More multinational pharmaceutical companies are also conducting early-stage clinical research
and submitting innovative drug applications in China alongside other major markets.
For Chinese drugmakers, stronger innovation is also creating new opportunities overseas.
We have established an AI-powered small molecule screening platform
that has shortened the validation of preclinical candidate compounds
from 18 to 24 months to less than 12 months.
Our recent partnerships with multinational pharmaceutical companies have focused
increasingly on technology platforms and innovative research capabilities.
Official data says Chinese innovative drug developers signed 81 overseas licensing deals
worth about $110 billion in the first half of this year, already reaching about 80% of last year's
total. The deals cover major therapeutic areas including oncology, metabolism, immunology,
and neurology, reflecting growing international collaboration in China's pharmaceutical
innovation.
